Actinogen Medical Ltd has released a press release.
Updated Xanamem Clinical Development Program
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- June 2018 Quarterly Report
- Placement under Share Purchase Plan Shortfall
- New Study Sites Added to Accelarate Patient Recruitment
- Share Purchase Plan
- $15m Placement Completed-Including US Cornerstone Investor
Later from Actinogen Medical
- XanADu Patient Enrolment Advancing Towards Completion
- DSMB reaffirms that XanADu continue without change
- Appendix 4E & Financial Statements
- R&D Tax Rebate Received Totalling $3.15 Million
- Recruitment to close for important Alzheimers trial-XanADu
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical